Leerink Partnrs Forecasts Lower Earnings for Exact Sciences

Exact Sciences Corporation (NASDAQ:EXAS) – Equities researchers at Leerink Partnrs dropped their Q1 2026 earnings estimates for shares of Exact Sciences in a note issued to investors on Tuesday, November 4th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $0.09 per share for the quarter, down from their prior estimate of $0.17. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q2 2026 earnings at $0.33 EPS, Q4 2026 earnings at $0.50 EPS and FY2027 earnings at $2.33 EPS.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.11. The company had revenue of $850.74 million for the quarter, compared to the consensus estimate of $810.42 million. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The firm’s quarterly revenue was up 20.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.21) EPS. Exact Sciences has set its FY 2025 guidance at EPS.

A number of other equities analysts also recently weighed in on the stock. Piper Sandler boosted their price target on shares of Exact Sciences from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. Robert W. Baird increased their target price on shares of Exact Sciences from $72.00 to $88.00 and gave the stock an “outperform” rating in a research report on Tuesday. Cowen reiterated a “buy” rating on shares of Exact Sciences in a research report on Tuesday. Royal Bank Of Canada cut their target price on shares of Exact Sciences from $54.00 to $46.00 and set a “sector perform” rating for the company in a research report on Thursday, August 7th. Finally, Craig Hallum increased their target price on shares of Exact Sciences from $65.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, September 11th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $73.44.

Exact Sciences Price Performance

Shares of NASDAQ:EXAS opened at $69.63 on Wednesday. The company’s 50-day moving average is $57.31 and its 200 day moving average is $53.14. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.56 and a current ratio of 2.89. The company has a market capitalization of $13.18 billion, a P/E ratio of -12.82, a price-to-earnings-growth ratio of 5.56 and a beta of 1.24. Exact Sciences has a fifty-two week low of $38.81 and a fifty-two week high of $72.81.

Insider Activity

In other news, Director James Edward Doyle sold 2,000 shares of the stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $60.00, for a total value of $120,000.00. Following the sale, the director directly owned 57,962 shares of the company’s stock, valued at approximately $3,477,720. This represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Exact Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of EXAS. Y Intercept Hong Kong Ltd bought a new position in shares of Exact Sciences in the second quarter worth approximately $3,716,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Exact Sciences in the first quarter worth approximately $34,000. Cerity Partners LLC grew its holdings in shares of Exact Sciences by 24.0% in the first quarter. Cerity Partners LLC now owns 33,598 shares of the medical research company’s stock worth $1,454,000 after purchasing an additional 6,508 shares during the last quarter. Teacher Retirement System of Texas bought a new position in shares of Exact Sciences in the first quarter worth approximately $1,171,000. Finally, Gagnon Securities LLC grew its holdings in shares of Exact Sciences by 3.0% in the second quarter. Gagnon Securities LLC now owns 278,789 shares of the medical research company’s stock worth $14,815,000 after purchasing an additional 8,125 shares during the last quarter. 88.82% of the stock is owned by hedge funds and other institutional investors.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.